Milestone Pharmaceuticals Inc.

NASDAQ:MIST

Biotechnology

Healthcare
$0.46 -0.01%

-$0.00 today

Market cap
$57.32M
Beta
0.96
P/E (TTM)
-2.5
EPS (TTM)
-$0.52
52W Low $1.00High $3.06

Volume 2.23M

Average 1.99M

MIST Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Milestone Pharmaceuticals Inc.NASDAQ: MIST

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was $168K, compared with $0 a year earlier. Trailing-twelve-month gross profit was $1.69M. Over 3 fiscal years it compounded at -34.1% a year.

Context

  • Gross profit amounted to 92.6% of revenue in FY2025.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near $168K or moves back toward the trailing-twelve-month quarterly average of $422.25K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$168K-89.1% QoQ
Last fiscal yearDec 2025
$1.43M— YoY
LTMMar 2026
$1.69M— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR-34.1%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
1.43M USD
Year-over-year change
—
4-year CAGR
-44.4%

Gross Profit vs competitors

How MIST compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Gross profit amounts to 94.7% of revenue for MIST, versus a peer median of 100.0%.
MIST Competitors
Gross Profit for MIST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$3.01M USD+150.7%—94.9%
IPHAInnate Pharma S.A.FY2025€2.79M EUR-77.9%-22.6%100.0%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$1.69M USD—-34.1%94.7%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$149K USD+99.1%——
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$289K USD+75.2%——
PEPGPepGen Inc.LTM Mar 2026-$1.72M USD-351.6%——
MOLNMolecular Partners AGLTM Mar 2026-CHF 2.61M CHF+91.8%——
CRDFCardiff Oncology, Inc.LTM Mar 2026-$11.06M USD-20.7%+15.4%2105.7%
Peer median (excluding MIST) —+75.2%-3.6%100.0%

Competitors are the stored peer set for MIST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue15M5M1M01.55M
Cost of Revenue0000114K
Gross Profit15M5M1M01.43M
Gross Margin100.0%100.0%100.0%—92.6%
Research & Development38.67M39.83M31.05M14.36M18.11M
Selling, General & Admin19.4M24.81M31.05M27.75M17.27M
Operating Expenses58.07M64.64M62.1M42.1M63.92M
Depreciation & Amortization93K89K92K105K114K
EBITDA(42.76M)(58.3M)(57.04M)(37.83M)(59.45M)
EBITDA Margin-285.1%-1166.0%-5703.9%—-3845.5%
Operating Income(43.07M)(59.64M)(61.1M)(42.1M)(62.49M)
Operating Margin-287.2%-1192.8%-6109.8%—-4041.7%
Interest Income220K1.25M3.97M4.16M2.92M
Interest Expense002.55M(3.58M)3.84M
Other Income / Expenses220K1.25M1.41M583K(918K)
Income Before Tax(42.85M)(58.39M)(59.69M)(41.52M)(63.4M)
Pre-Tax Margin-285.7%-1167.8%-5968.5%—-4101.1%
Income Tax Expense0000(345K)
Net Income(42.85M)(58.39M)(59.69M)(41.52M)(63.06M)
Net Margin-285.7%-1167.8%-5968.5%—-4078.8%
EPS (Basic)(1.02)(1.35)(1.39)(0.67)(0.75)
EPS (Diluted)(1.02)(1.35)(1.39)(0.67)(0.75)
Weighted Avg Shares41.83M42.45M42.96M62.21M83.88M
Weighted Avg Shares (Diluted)41.83M42.45M42.96M62.21M83.88M

Milestone Pharmaceuticals Inc.

NASDAQ:MIST

Intrinsic Alpha fair value

Locked

Current Price

$0.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.